| Literature DB >> 30347212 |
André Moraes Nicola1, Patrícia Albuquerque2, Hugo Costa Paes3, Larissa Fernandes2, Fabricio F Costa4, Erika Seki Kioshima5, Ana Karina Rodrigues Abadio6, Anamélia Lorenzetti Bocca7, Maria Sueli Felipe8.
Abstract
The need for better antifungal therapy is commonly accepted in view of the high mortality rates associated with systemic infections, the low number of available antifungal classes, their associated toxicity and the increasing number of infections caused by strains with natural or acquired resistance. The urgency to expand the range of therapeutic options for the treatment of fungal infections has led researchers in recent decades to seek alternative antifungal targets when compared to the conventional ones currently used. Although new potential targets are reported, translating the discoveries from bench to bedside is a long process and most of these drugs fail to reach the patients. In this review, we discuss the development of antifungal drugs focusing on the approach of drug repurposing and the search for novel drugs for classical targets, the most recently described gene targets for drug development, the possibilities of immunotherapy using antibodies, cytokines, therapeutic vaccines and antimicrobial peptides.Entities:
Keywords: Antifungal immunotherapy; Drug discovery and development; Drug targets; Essential genes; Rational drug design; Systemic mycoses
Mesh:
Substances:
Year: 2018 PMID: 30347212 DOI: 10.1016/j.pharmthera.2018.10.008
Source DB: PubMed Journal: Pharmacol Ther ISSN: 0163-7258 Impact factor: 12.310